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Glioblastoma (GBM), the most common brain malignancy, remains
fatal with no effective treatment. Analyses of common aberra-
tions in GBM suggest major regulatory pathways associated with
disease etiology. However, 90% of GBMs are diagnosed at an
advanced stage (primary GBMs), providing no access to early dis-
ease stages for assessing disease progression events. As such, both
understanding of disease mechanisms and the development of
biomarkers and therapeutics for effective disease management
are limited. Here, we describe an adult-inducible astrocyte-specific
system in genetically engineered mice that queries causation in
disease evolution of regulatory networks perturbed in human
GBM. Events yielding disease, both engineered and spontaneous,
indicate ordered grade-specific perturbations that yield high-grade
astrocytomas (anaplastic astrocytomas and GBMs). Impaired reti-
noblastoma protein RB tumor suppression yields grade II histopa-
thology. Additional activation of v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS) network drives progression to grade III
disease, and further inactivation of phosphatase and tensin homo-
log (PTEN) yields GBM. Spontaneous missense mutation of tumor
suppressor Trp53 arises subsequent to KRAS activation, but before
grade III progression. The stochastic appearance of mutations
identical to those observed in humans, particularly the same spec-
trum of p53 amino acid changes, supports the validity of engi-
neered lesions and the ensuing interpretations of etiology. Absence
of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic low
grade disease, and rapid emergence of GBM combined with a mes-
enchymal transcriptome signature reflect characteristics of pri-
mary GBM and provide insight into causal relationships.
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Astrocytomas are the most common malignant brain tumors.Overall survival for patients with diffuse astrocytoma [A2;
World Health Organization (WHO); grade II], anaplastic as-
trocytoma (AA; WHO grade III), and glioblastoma (GBM;
WHO grade IV) has not significantly changed in the past 50 y
and remains at 8–10 y, 2–3 y, and 9–12 mo, respectively (1).
High-grade astrocytomas (AA and GBM, HGAs), for which
there is no curative treatment (1), are characterized by aggressive
diffuse brain invasion, cytological pleomorphism, and elevated
mitotic activity, with GBM additionally showing microvascular
proliferation (MVP) and/or necrosis. Although some GBMs arise
subsequent to a previously diagnosed low-grade glioma (secondary
GBM), 90% appear without prior clinical history (primary GBM),
thus precluding insight into disease progression (2).
Most GBMs harbor aberrations in three major signaling net-
works, with tumor-specific lesions occurring at various known
pathway points (2, 3). Seventy to 90% of GBMs carry lesions in
CDKN2A/CDK4-CyclinD/RB, receptor tyrosine kinase (RTK)/
RAS/PI3K/PTEN, and MDM2/CDKN2A(ARF)/p53 networks.
However, based on global transcriptome studies, several distinct
GBM molecular subtypes exist that may manifest in distinct clin-
ical and/or therapeutic outcomes (2–6). Given the critical role of
the microenvironment in cancer evolution, comprehensive ex-
amination of astrocytoma etiology requires assessment of both
engineered and spontaneous molecular aberrations in vivo. Genet-
ically engineered mouse (GEM) models provide an experimental
format for such studies and may offer promise for preclinical
development of therapeutics and diagnostics (7–9). Although
several studies have reported combinations of genetic events that
can predispose to GEM-HGA, specific contributions to disease
stages and evolutionary patterns have yet to be elucidated.
Here, we dissected the relative roles of inactivating retino-
blastoma protein (RB)-tumor suppression (TS), activating the
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
network and inactivating phosphatase and tensin homolog
(PTEN) in GBM etiology. We examined tumor evolution for
evidence of spontaneous mutation of tumor suppressor Trp53
and/or PTEN deletion in conjunction with engineered events and
report progression of events that yield HGAs possessing a spec-
trum of heterogeneous molecular and histological disease fea-
tures typical of human astrocytomas. The study provides unique
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insights that distinguish contributions to initiation and progression
in the transition from low- to high-grade disease.
Results
Adult-Inducible Targeting of Networks Commonly Perturbed In Hu-
man GBMs. Based on the prominent networks frequently aberrant
in GBMs, we examined contributions to disease etiology upon
RB-TS and/or PTEN inactivation and/or KRAS activation singly
and in all combinations. Events were targeted to adult astrocytes
using 4OHT-directed activation of CreERT2 expressed from a
human glial fibrillary acidic protein (hGFAP)-CreERT2 transgene
(10) (Fig. S1). In the adult brain, GFAP-directed transgene ex-
pression is restricted to mature astrocytes and adult neural stem
cells (10). RB-TS was conditionally abolished by Cre-dependent
expression of T121, which dominantly inactivates RB and com-
pensatory proteins p107 and p130 (11). Upon exposure to Cre,
TgGZT121 transgenic mice switch from LacZ expression to T121
expression, also under GFAP regulatory control (12). KRAS,
commonly hyperactivated in GBMs (5, 13), was activated via
Cre-conditional endogenous-level induction of the KRAS+/lsl-G12D
allele (14). Finally, we examined the impact of homozygous or
heterozygous PTEN deletion.
Events were induced by 4OHT intraperitoneal (IP) injec-
tion of 3-mo-old animals (Fig. S1A). All genotypes post-4OHT
treatment are abbreviated herein as shown in Fig. S1B: T = TgG
(ΔZ4OHT)T121;hGFAP-CreER
T2, R = KRASG12D;hGFAP-CreERT2,
PL/L = PTENL/L; hGFAP-CreERT2, and PL/+ = PTENL/+;hGFAP-
CreERT2. Cre activation was validated by allele-specific PCR of
TR brain DNA (Fig. S2A and Table S1) and immunostaining for
T121 (Fig. S2B). Deletion of loxP-flanked cassettes was readily
apparent post induction (p.i.). By 2 wk p.i., T121-expressing cells
(present only in induced brains) were also positive for GFAP
(cytoplasmic astrocyte marker) and S100β (nuclear/cytoplasmic
glial marker) (Fig. S2C).
Only RB-TS Inhibition Initiates Disease. Of the three single events
targeted to adult astrocytes, only loss of RB-TS function was
sufficient to initiate astrocytomagenesis (Figs. 1A and 2A) based
on the induction of grade II-like histopathology (Fig. 1 A, c).
Neither KRASG12D activation nor PTEN inactivation, alone or in
combination (Fig. 1 A, b), produced detectable brain pathology
(Fig. 2A). In T mice, grade II pathology was detectable within
2 wk of induction and became more cellular with time (Fig.
S2D). Atypical astrocytes proliferated aberrantly (Fig. 1B and
Fig. S3A), had an increased apoptotic rate (Fig. 1B and Fig.
S3A), and, as in the human disease, associated extensively with
neurons and vasculature (perineuronal and perivascular satel-
litosis; secondary structures of Scherer) (Fig. S2 D, f and D, j).
Two of 11 aged T mice (18%) at 455 and 537 d p.i. harbored
diffuse grade III pathology based solely on mitotic activity. No
tumor masses were present.
Roles for KRAS Activation and PTEN Deletion in Progression to HGA.
To test whether KRAS activation and/or PTEN deletion or het-
erozygosity would accelerate and/or progress disease, these
events were combined with RB-TS inactivation, singly and to-
gether. Neither AA nor GBM appeared in TPL/+ or TPL/L mice
(Fig. 2A) although the cellularity of grade II astrocytoma was
accelerated in TPL/L brains (Fig. 1 A, d), consistent with previ-
ous results in which PTEN haploinsufficiency (12) or focal PTEN
deletion (15) reduced RB-TS inactivation-induced apoptosis. In
contrast to PTEN deletion, the combination of RB-TS loss and
KRASG12D expression (TR mice) dramatically shortened survival
(median = 150 d p.i.) compared with RB-TS loss alone (no lethal
brain malignancy up to 537 d) (Fig. 2). In TR mice, lethal masses
consistently progressed from the background of widespread
grade II pathology (Fig. 1 A, e and A, g). Ten of 13 TR mice
(77%) developed lethal AA based on the presence of masses with
extensive mitoses (Table S2). The remaining masses (3 of 13;
23%) were GBMs based on the additional presence of small
necrotic centers; these tumors likely reflect stochastic progression
via additional oncogenic event(s) (see next paragraph). A single
TR mouse requiring premature euthanasia due to thymic hyper-
plasia (see below and Table S2) had also developed diffuse grade
III astrocytoma.
Unlike the combination of Rb-TS inactivation and PTEN de-
letion, impaired PTEN function together with RB-TS loss and
KRASG12D expression in TRPL/+ and TRPL/L astrocytes led
to reduced median survival (132 d and 84 d p.i., respectively)
compared with TR mice (150 d) (Fig. 2). Sixty percent (12 of 20)
of TRPL/+ and 88% (7 of 8) of TRPL/L animals developed lethal
necrotic GBM (Table S2 and Fig. 1 A, j). For each genotype,
tumor development occurred within a reproducible time p.i.. As
in humans, GEM-GBMs were invasive as evidenced by infiltrative
interfaces (Fig. 1 A, i) and the frequent presence of necrosis (Fig. 1
A, j). By RNA in situ hybridization, VEGF expression was evident
in perinecrotic tumor cells (Fig. 1 A, k and A, l). GBMs were
astrocytic as shown by GFAP, nestin, and olig2 positivity and
synaptophysin (a neuronal marker) negativity (Fig. S2E). Skin
and thymic lesions arose in some TRPL/+ and TRPL/L mice due to
Fig. 1. Characterization of GEM astrocytomas. (A) H&E-stained
mouse brain and tumor sections of indicated genotypes as de-
scribed in Results. Invasiveness (i) and pseudopalisading necrosis
(j) were observed in GBMs. In situ hybridization detected VEGF
mRNA expression in perinecrotic GBM cells (l, arrow) as shown
in the H&E-stained serial section (k). (B) Quantification of
Ki67 (left y axis, black-bordered bar) and TUNEL (right y axis,
blue bar) in cortex of mice of indicated genotypes 2 wk p.i..
Data are presented as mean ± SEM.
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GFAP–driven recombination in these tissues (16, 17), thus pre-
cluding assessment of terminal brain disease (Fig. S3 D and E
and Table S2). However, all brains minimally contained signifi-
cant diffuse astrocytoma pathology consistent with the age at
termination.
Astrocyte inactivation of RB-TS in adult central nervous system
(CNS) led to aberrant astrocyte proliferation and apoptosis (Fig.
1B and Fig. S3A). We assessed acute effects on astrocyte pro-
liferation and apoptosis to determine relative acute contributions
of progression events, KRASG12D expression (TR brain at 2 wk p.i.)
and subsequent PTEN deletion (TRPL/L brain at 2 wk p.i.). Com-
pared with T mice, astrocyte apoptosis was significantly decreased
upon KRASG12D expression and was further reduced with PTEN
deletion (Fig. 1B and Fig. S3A). There were no significant in-
creases in proliferation. This observation is consistent with the
hypothesis that pAkt downstream of PI3K may be the effector of
increased survival because its activity can be induced downstream
of RAS-triggered PI3K activation and further enhanced upon loss
of PI3K negative regulator PTEN. By this mechanism, apoptosis
provides a selective pressure for loss of PTEN function during
GBM evolution. Indeed, KRASG12D activation is required in this
model to facilitate stochastic loss of PTEN (see Spontaneous
PTEN Loss and Trp53 Mutations Validate Evolutionary HGA Pro-
gression and Identity with Human Disease).
HGA Development Is Dictated by Genetic Lesions. In the above
studies, HGA development could reflect true cause–effect rela-
tionships in human disease progression; however, it was possible
that the widespread astrocyte abnormality created by diffuse
induction of genetic events had artificially contributed to disease.
To distinguish these possibilities, we focally induced the genetic
lesions that predisposed to GEM-GBM (astrocyte-specific RB-TS
inactivation, KRASG12D activation, and PTEN loss or heterozy-
gosity) by stereotactic introduction of self-deleting Cre-lentivirus
into the frontal cortex of TRPL/+ and TRPL/L mice without the
hGFAP-CreERT2 allele (Fig. S3B). Focal induction led to GBM
development with histopathology identical to that developed in
broadly induced brains in 3/5 TRPL/+ and 3/5 TRPL/L mice. Thus,
GBM was caused by the engineered and associated evolving
lesions and not as a secondary result of widespread gliosis. As
expected, no skin or thymic lesions developed when genetic lesions
were induced focally in brain. These results confirm the inter-
pretation of cause/effect relationships derived from diffuse astro-
cyte induction studies described above.
Spontaneous PTEN Loss and Trp53 Mutations Validate Evolutionary
HGA Progression and Identity with Human Disease. Although sig-
nificant molecular and biological aspects of human HGA are rep-
resented in these GEM models, it was possible that engineered
events inappropriately produced such similarity but did not
reflect the natural evolution of human disease. Thus, we assessed
the stochastic loss of wild-type PTEN alleles in GBMs of TR (two
wild-type PTEN alleles) and TRPL/+ (one wild-type PTEN allele)
mice. As described above, engineered PTEN deletion in the
context of RB-TS loss and KRAS activation (TRPL/L mice) drives
GBM progression, and PTEN deletion is frequent in human
GBMs. Quantitative PCR assessment of tumor DNA showed
that, among 8 samples from 6 TR-derived tumors, 5 (63%) had
lost one allele, and 2 (25%) had lost both PTEN alleles (Table
S3). Of 12 samples from 9 TRPL/+ tumors, 7 (58%) had lost the
WT PTEN allele. Of the 5 tumors (2 TR and 3 TRPL/+) that were
analyzed from 2 distinct regions, 3 tumors (2 TR and 1 TRPL/+)
showed intratumoral heterogeneity of wild-type PTEN allele loss.
Three TRPL/+ samples appeared to retain both PTEN alleles, in-
dicating either that recombination had not occurred in that region
or that PTEN wild-type astrocytes had assumed tumor-cell prop-
erties within the tumor microenvironment (18). By similar analy-
ses, grade II astrocytomas retained both PTEN alleles, consistent
with KRASG12D expression being required, directly or indirectly,
to establish the pressure for PTEN inactivation selection.
Eighty-seven percent of human GBMs harbor p53 network
aberrations, with 42% of these having p53 missense mutations
and only 1% with p53 homozygous allele loss (5). We assessed
GEM-GBMs by IHC for p53 accumulation (indicative of muta-
tion) and subcellular localization. Tumors, but not adjacent
regions, expressed high p53 levels (Fig. 3 A, c and A, e). DNA
sequencing of 18 GBMs revealed that 10 (56%) harbored Trp53
missense mutations, 1 (∼6%) carried a frame-shift mutation, and
1 (∼6%) a splice site acceptor mutation at the −1 position of
Trp53 exon 5 (Fig. 3B and Table S4). Most of the missense
mutations were analogous to those observed in human GBMs,
and all have been observed in human cancers (http://p53.iarc.fr/;
IARC TP53 database R16) (19). In addition, of the 6 GBMs that
contained wild-type p53 coding exons, p53 was mislocalized to
the cytoplasm in 4 (67%) (Fig. 3 A, h and A, i and Table S4). Of
unknown significance, the 2 tumors that expressed nuclear wild-
type p53 carried intronic base changes not represented in SNP
databases (Table S4). GBMs induced focally via lentivirus-driven
Cre injection also expressed p53 mutants (Fig. 3 A, m and A, n).
Furthermore, HGAs induced both by systemic and focal in-
duction methods appeared to be heterogeneous for p53 changes
based on the observation that not all tumor cells within a given
mass had accumulated p53 (e.g., Fig. 3 A, c and A, e). As with
PTEN allele loss, this observation could indicate that wild-type
cells within the tumor mass may assume abnormal properties due
to paracrine mechanisms.
To determine the stage(s) in tumor progression in which
stochastic p53 mutation/mislocalization arose, we assessed p53
immunopositivity in brains of T, TR, TRPL/+, and TRPL/L mice at
various ages (Table S5). Early p53-positive nodules consistently
Fig. 2. Analysis of genotype-associated astrocytoma pheno-
types. (A) Brain histopathology of mice at the time of sacrifice
p.i. (y axis) is shown (colored shapes). Mice were euthanized at
several time points for analysis or when tumors were apparent.
Brain tumor (BT) as cause of death (COD): mice were killed due
to neurological or physical signs of CNS abnormality and a
brain tumor was confirmed; COD other than BT: scheduled
analysis time point with no sign of abnormality and mice with
non-BT masses. The highest brain pathology grade present is
indicated. Genotypes of mice induced with 4OHT at 3 mo of
age are indicated on the x axis: T = TgG(ΔZ4OHT)T121;hGFAP-
CreERT2+/−, R = KRASG12D;hGFAP-CreERT2+/−, PL/L = PTENL/L;
hGFAP-CreERT2+/−, RPL/L = KRASG12D;PTENL/L;hGFAP-CreERT2+/−,
TPL/+ = TgG(ΔZ4OHT)T121;PTEN
L/+;hGFAP-CreERT2+/−, TPL/L = TgG(ΔZ4OHT)T121;PTEN
L/L;hGFAP-CreERT2+/−, TR = TgG(ΔZ4OHT)T121;KRAS
G12D;hGFAP-CreERT2+/−,
TRPL/+ = TgG(ΔZ4OHT)T121;KRAS
G12D;PTENL/+;hGFAP-CreERT2+/−, and TRPL/L = TgG(ΔZ4OHT)T121;KRAS
G12D;PTENL/L;hGFAP-CreERT2+/−. R, P, and RP mice were
grouped as R;P;RP because none developed brain pathology. NL, normal. (B) Kaplan–Meier analysis of astrocytoma-specific tumor-free survival after 4OHT
administration in GEMs. Median survival for TR, TRPL/+, and TRPL/L mice was 5, 4.4, and 2.8 mo, respectively. Mice with COD other than brain tumor or
unknown COD were censored (tick marks). T, TPL/+, and TPL/L mice did not develop life-threatening disease although diffuse grade II astrocytoma pathology
was consistently present. Numbers of mice analyzed: R;P;RP (n = 32), T (n = 11), TPL/+ (n = 8), TPL/L (n = 11), TR (n = 21), TRPL/+ (n = 28), and TRPL/L (n = 17).
Littermate control mice (either hGFAP-CreERT2 negative or vehicle injected) were not plotted due to lack of phenotype.






emerged within 2–3 mo p.i. only in mice predisposed to HGA
(TR, TRPL/+, and TRPL/L mice). Nodules appeared before mass
formation and expressed abundant p53 in either the nucleus or
cytoplasm (Fig. 3 A, b; A, d; and A, f–i). Indeed, based on se-
quencing, 5 of 8 (62.5%) AA (GIII) tumors harbored sponta-
neous Trp53 mutations, 2 (25%) had wild-type Trp53, and 1
carried intronic base changes (Fig. 3B and Table S4). Despite
active grade II (GII) disease, T brains did not detectably express
p53. The presence of a small number of p53 positive cells
detected in 36% (5 of 14) of 12- to 23-mo-p.i. brains may indicate
the accumulation of multiple stochastic changes reflecting early
progression (Fig. 3 A, j and A, k and Table S5).
Human Disease Properties in GEM-GBM. In primary GBM, the first
clinical symptoms occur after advanced disease is present. Sim-
ilarly, overt physical signs of low-grade disease were not observed
in GEMs until HGA was present in TR, TRPL/+, and TRPL/L
mice. To determine how quickly HGA developed, we monitored
tumor development by serial magnetic resonance images (MRI)
in TRPL/+ mice. Masses were readily detectable grossly (Fig. S3
C, a) or with MRI (Fig. S3 C, d), and, as in human (20), com-
puter-enhanced vascular reconstruction analysis revealed exten-
sive vessel tortuosity both intrinsic and adjacent to tumor masses
(Fig. S3 C, b). To monitor tumor development, scans were per-
formed biweekly starting at 14 wk p.i., and tumor volumes were
calculated using ImageJ software (Fig. 4A). Lesions were de-
tectable in all TRPL/+ mice between 16 and 23 wk p.i.. Within
a 2-wk interval, 9 of 11 animals (82%) transitioned from a tiny
detectable lesion (1.037–6.194 mm3) to a large life-threatening
mass (2.609–79.355 mm3) (Fig. 4A) (animal ID 1–9). In the time
frame of this experiment, two mice (18%) had a detectable le-
sion only at the terminal imaging session (Fig. 4A) (animal IDs
10 and 11; 17.235 mm3 and 6.5505 mm3, respectively). Mice were
moribund within 1 wk after detecting a mass, with only one ex-
ception (Fig. 4A) (animal ID 1; within 2 wk). Thus, tumor growth
subsequent to major progression event(s) follows a rapid lethal
course, possibly explaining symptomless early disease associated
with primary GBM in humans.
To determine whether GEM-GBMs recapitulated specific mo-
lecular subtypes of human primary GBMs, we performed tran-
scriptome analysis using the orthologous 840-gene classifier set
identified by Verhaak et al. (21). Thirty of 44 GBMs (68%)
clustered with the mesenchymal subclass, the most aggressive of
the human classes, 12 (27%) with the proneural, and 2 (5%) with
the neural subgroups (Fig. 4B). No tumors clustered with the
classical subtype. The predominance of mesenchymal-like GEM-
GBM is consistent with the observation that this human subtype
correlates with a high rate of mutation in RB1 (13%), NF1 (37%,
indicative of KRAS activation), PTEN (32%), and TP53 (32%)
compared with other subtypes (21). However, the clustering of
molecular subtypes does not align with specific genotypes of
GEMs, indicating some heterogeneity in GBM development and
possible association with stochastic progression events. Recently,
murine GBMs induced via stereotactic introduction of a lentivirus
expressing HRAS and shRNA suppressing p53 function were also
shown to harbor a mesenchymal transcriptome signature (22),
further supporting alignment of this class with aberrant RAS and
p53 functions.
Somatic isocitrate dehydrogenase 1 (IDH1) mutations are pres-
ent in 73–85% of secondary and in only 3.7–4.9% of primary
GBMs (23, 24). Among the primary GBMs, the mesenchymal
subtype was not associated with IDH1 mutation, where 30% of
the proneural subtype was shown to harbor IDH1mutations (21).
Consistent with the majority of GEM-GBMs harboring a mes-
enchymal phenotype, no IDH1 mutations were detected by DNA
sequencing in GEM-grade II (n = 5), GEM-AA (n = 18), or
GEM-GBM (n = 15) tissues. Together, the GEM-GBM phe-
notype, absence of IDH1 mutations, predominance of the mes-
enchymal transcriptome subclass, and rapid asymptomatic tumor
development findings indicate that the GEM-GBMs are most
characteristic of human primary disease.
Discussion
We used combinations of engineered alleles along with analyses
of stochastic genetic changes to probe the etiology of high-grade
astrocytomas (HGAs) in GEMs. Three major networks per-
turbed in most human GBMs (RTK/RAS/PI3K/PTEN, p53, and
RB signaling) contributed to distinct disease stages. RB tumor
suppression (TS) inhibition was required to initiate disease, with
constitutive perturbation of KRAS signaling followed by stochastic
p53 aberration driving the transition from low- to high-grade dis-
ease and yielding grade III tumors (AA). Additional PTEN loss
(engineered or stochastic) drove progression to grade IV (GBM)
(summarized in Fig. 4C). These conclusions were possible based on
Fig. 3. p53 status in TR and TRPL tumors and cortex. (A) Rep-
resentative images of p53 IHC staining at different p.i. time
points in systemic-induced T, TR, and TRPL brains (a–k) and
lenti-Cre induced TRPL brain (l–n). Accumulation of p53 was
evident in nucleus (b–g, j, k, and m) or cytoplasm (h, i, and n).
p53 accumulation appeared in early clusters/nodules (b and f;
d and g; and h and i). ctx, cortex; mo, months p.i.. p53 was
negative in the remaining brain of lenti-Cre induced brain (l).
(B) Trp53 missense mutations and frame shifts identified in TR,
TRPL/+, and TRPL/L HGAs (Upper) and corresponding human
TP53 missense mutations present in human GBMs (Lower). All
samples were from fresh frozen HGA tissues except italicized
samples, which were from primary cells generated from HGA
or cortex region. Same color of blue or red indicates that tissue
samples were taken from the same animal but different
regions (one from tumor mass and the other from non-tumor
mass cortex region). All tumors were diagnosed as GBM except
asterisk-labeled (AA). †In frame insertion; ‡Frame shift; §Cor-
responding frame shift found in human GBMs; parentheses,
number of tumors that had the same missense mutation.
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the following logic. Of all single events and double combinations,
only RB-TS inactivation initiated disease and resulted in GII pa-
thology. Of double combinations, only the combination of Rb-TS
inactivation and KRASG12D induction predisposed to GIII tumors.
Finally, either stochastic loss of PTEN from GIII tumors or
engineered PTEN deletion along with Rb-TS inactivation and
KRASG12D induction drove GBM (GIV) progression.
Astrocytoma Initiation. Recent studies have reported event com-
binations within the same major GBM-perturbed networks that
predispose to GEM-GBM, wherein engineered events were in-
sufficient for initiation, thus limiting analysis of disease evolu-
tion. In this study, RB-TS inactivation acutely induced low-grade
disease. That no brain pathology was caused by KRASG12D induc-
tion or PTEN deletion or both combined is consistent with other
recent reports examining adult brain (25–28). The RB network
is perturbed in most human GBMs. Although CDKN2A locus
[CDKN2A (p16/INK4A) and CDKN2B (p15/INK4B)] deletions
are the most frequent events (50–55%), aberrations can occur at
multiple points, including CDKN2C (p18/INK4C) deletion (2%),
CDK gene amplification (CDK4, 18%; CDK6, 1%), or RB1 deletion/
mutation (11–12%) (5, 6). In mouse, deletion of INK4A does not
elicit brain pathology (29, 30). There is clear redundancy among
the CDKNs in mouse tissues (31) as there is among RB family
members. Directly modeling RB-TS inactivation in mouse astro-
cytes, as well as in most other cell types, requires inhibition of
multiple RB family proteins (32–34). Thus, use of a single allele
to disable RB, p107, and p130 via the dominant activity of T121
was key to exploring role(s) of RB-mediated TS, and thus GBM
initiation. In Chow et al. (25), HGA predisposed by adult as-
trocyte PTEN and p53 deletion often carried copy-number
alterations in genes acting upstream of RB (e.g., CDK4, CDK6,
CCND1, CCND2, and CCND3 amplification), supporting a role
for stochastic perturbation of this network. Although RB1 de-
letion alone did not yield disease, it could reduce the latency of
HGAs predisposed by codeletion of PTEN and p53, and several
resulting tumors had also amplified the E2F3 gene (25).
HGA Progression: A Model for Disease Evolution. KRASG12D in-
duction was required for progression to HGA. Although sto-
chastic KRASmutation is rare in human GBM (∼2%) (5), KRAS
regulators are frequently aberrant (see Introduction). Causal
roles for RAS network aberrations in GEM-HGA have been
confirmed in several engineered mouse studies. Unique to the
current study is placement of the RAS activation impact at the
transition from low- to high-grade disease and before GBM
formation in the context of RB network perturbation. Engi-
neered PTEN deletion alone could not drive HGA from low-
grade astrocytoma (induced by RB-TS inactivation); however,
engineered or stochastic PTEN loss was associated with pro-
gression of AA to GBM. Thus, KRASG12D-driven pathway(s)
and/or subsequent stochastic events provide selective pressure(s)
for PTEN inactivation in the evolution from GIII to GIV dis-
ease. Consistent with results herein and with previous observa-
tions is the possibility that the PI3K network, activated by KRAS
and negatively regulated by PTEN, is involved. Consistent with
the hypothesis that RAS network perturbation is required for
driving high-grade astrocytoma, Chow et al. also observed nu-
merous stochastic RTK (MET, EGFR, and PDGFR) amplifi-
cations in engineered p53/PTEN-deficient GEM-HGAs (25).
Stochastic p53 Missense Mutation in HGA Evolution. In previous
reports, Trp53 and PTEN deletion in embryonic radial glial cells
(35) or adult astrocytes (25, 36) predisposed mice to GEM-
HGA. Relative contributions to disease could not be assessed.
The predominant p53 aberration in human GBMs, missense
mutation (5, 35), wasn’t previously examined. Here, we chose not
to engineer p53 mutations, but rather to assess emerging tumors
for the presence of stochastic p53 mutation. This approach fa-
cilitated assessment of p53 mutation requirement in HGA evo-
lution, of spontaneously selected mutation type(s), and of the
validity in modeling HGA. Strikingly, as in humans, most GEM-
GBMs expressed missense mutant p53, with mutations analo-
gous to those found in human GBMs. Total p53 loss was not
observed although cytoplasmic mislocalization of wild-type p53
occurred in several cases. p53 accumulation first appeared in
early nodules predisposed by the combination of RB-TS inhi-
bition and KRAS activation, with or without PTEN inactivation.
Thus, KRAS directly or indirectly positively selected for p53
missense mutant or mislocalized cells. Recent assessment of high-
grade gliomas derived from cultured mouse PTEN−/− ;INK4a/
ARF−/− neurospheres orthotopically injected into immunocom-
promised mice also detected two Trp53 missense mutations (37).
Primary vs. Secondary GBM. Primary and secondary GBMs are
defined by clinical presentation, with the former presenting as
HGA and the latter appearing subsequent to previously di-
agnosed low-grade disease. Some tumor characteristics are more
prominent in one class compared with the other, but these divi-
sions are not absolute. For example, although IDH1mutations are
present in 73–85% of secondary GBMs, they also appear in 4–5%
of primary GBMs. Although GBMs with a mesenchymal tran-
scriptome signature are dominated by the primary class, second-
ary GBMs can also harbor this signature. The current study has
produced relevant models of low- and high-grade disease, with
evident tumor heterogeneity and the majority of GBMs having
transcriptional similarity to the aggressive human mesenchymal
subtype (4, 5, 38). Because tumors did not carry IDH1 mutations
and arose rapidly without prior evidence of symptoms, they most
closely resemble primary GBMs. Given that the models may
represent etiology of a primary GBM subset, they could provide
the first insight into possible evolutionary mechanisms and early
disease stages. Overlap in tumor evolution mechanisms among
some secondary and primary GBMs is likely, with the determin-
ing features of clinical presentation lying outside the actual
Fig. 4. Disease development, molecular characterization, and model for
GEM-GBM etiology. (A) Tumor volume was measured by biweekly T2-
weighted magnetic resonance images (MRI) in TRPL/+ mice starting at 14 wk
p.i.. (B) Microarray analysis of RNA from 44 GBMs (TR, TRPL/+, and TRPL/L
animals) was clustered with TCGA human GBM data using 840 classifiers
identified by Verhaak et al. (21). Genes were ordered based on predictive
subtypes. Mouse tumor data are denoted with black boxes and align as
follows: Proneural (n = 12), Neural (n = 2), Classical (n = 0), and Mesenchymal
(n = 30). (C) A model of astrocytoma molecular pathogenesis based on study
results. RB-TS inhibition, modeled here through expression of T121, is neces-
sary and sufficient to initiate the neoplastic process (grade II disease). Con-
stitutively activated KRASG12D is not sufficient for astrocytoma initiation but
rather is required for progression to high-grade tumors, in part by imposing
selection for spontaneous Trp53 mutation/mislocalization that occurs before
grade III mass formation. PTEN loss (spontaneous or engineered) contributes
to grade IV (GBM) progression only after RAS activation and p53 alteration.






mechanism(s) of evolution. The use of relevant disease models for
discovery of early disease biomarkers and mechanisms of etiology
may help elucidate clinically relevant features amenable to dis-
ease prevention, intervention, and management.
Materials and Methods
Genetically Engineered Mice and Systemic Induction. TgGZT121 conditional
transgenic mice (12) were maintained by crossing to BDF1 mice, and KRASG12D
(39), PTENL/L (40), and hGFAP-CreERT2 (10) mice to C57BL/6J mice. Genetic
events were induced by injecting freshly prepared 4-OH-tamoxifen (4OHT;
Sigma) intraperitoneally into adult mice (mean 3.5 ± 0.6 mo) with 1 mg per
mouse per day for 5 consecutive days (see SI Materials and Methods for 4OHT
preparation and genotyping). Methods described herein have been approved
by the Institutional Animal Care and Use Committees at the University of
North Carolina-Chapel Hill and at the National Cancer Institute-Frederick.
Microarray Transcriptome Analysis. Total RNA was extracted from frozen
tumor tissues using Qiagen RNeasy. Affymetrix mouse 430.2 array or Custom
Agilent SurePrint microarrays were performed following standard protocols
by the LMT (Science Applications International Corporation-Frederick) and
the Institute for Systems Biology microarray core. Microarray data were
processed and analyzed with R/Bioconductor packages and Gaggle software
platform (41). Each gene in the mouse tumor data was median-centered and
divided by its SD. The transformed data were clustered together with human
TCGA GBM data using the 840 classifiers identified by Verhaak et al. (21). All
raw data are publicly available (GEO26069).
Trp53 and IDH1 Sequencing. Genomic DNA was prepared from HGA tumor
tissues, cortex, or primary GEM-GBM cells. All 11 exons including UTRs of
Trp53 and all coding exons for IDH1 were PCR amplified and Sanger se-
quenced by the LMT.
Additional Methods. More detailed methods are shown in SI Materials and
Methods, and antibody information is shown in Table S6.
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